N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling

MLA

Yingying Shi, et al. “N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling.” Frontiers in Pharmacology, vol. 11, May 2020. EBSCOhost, https://doi.org/10.3389/fphar.2020.00593.

APA

Yingying Shi, Mingxia Zhou, Junkai Yan, Zizhen Gong, Jin Wu, Yuanwen Chen, & Yingwei Chen. (2020). N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.00593

Chicago

Yingying Shi, Mingxia Zhou, Junkai Yan, Zizhen Gong, Jin Wu, Yuanwen Chen, and Yingwei Chen. 2020. “N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling.” Frontiers in Pharmacology 11 (May). doi:10.3389/fphar.2020.00593.